GLP-1vsSLU-PP-332

GLP-1 (glucagon-like peptide 1) is the native incretin hormone produced by enteroendocrine L-cells in the distal small intestine and colon in response to nutrient ingestion. It is the endogenous molecule that all GLP-1 receptor agonist drugs (semaglutide, liraglutide, etc.) are designed to mimic. Understanding native GLP-1 is essential to understanding the entire drug class built upon its biology.

Upon release, GLP-1 binds to GLP-1 receptors (GLP-1R) — G protein-coupled receptors expressed on pancreatic beta cells, the GI tract, the heart, the kidneys, and critically, the brain. In the pancreas, GLP-1R activation stimulates adenylyl cyclase, raising intracellular cAMP levels, which potentiates glucose-stimulated insulin secretion. This glucose-dependence is a key safety feature — GLP-1 only promotes insulin release when blood sugar is elevated, minimizing hypoglycemia risk. Simultaneously, GLP-1 suppresses glucagon secretion from alpha cells, further reducing hepatic glucose output.

In the brain, GLP-1 receptors in the hypothalamus (arcuate nucleus, paraventricular nucleus) and brainstem (area postrema, nucleus tractus solitarius) mediate appetite suppression and satiety. GLP-1 also activates vagal afferents to slow gastric emptying, prolonging nutrient absorption and post-meal satiety. The critical limitation of native GLP-1 is its extremely rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), which cleaves the first two amino acids within 1-2 minutes, rendering it inactive. This ultra-short half-life is why pharmaceutical GLP-1 analogues require structural modifications (albumin binding, DPP-4 resistance) to achieve clinically useful durations of action.

SLU-PP-332 is a small molecule agonist of estrogen-related receptor alpha (ERRα), one of three orphan nuclear receptors in the ERR family. Despite its name, ERRα does not bind estrogen — it was named for its structural similarity to estrogen receptors. ERRα is constitutively active and functions as a master transcription factor for genes controlling mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation, particularly in metabolically active tissues like skeletal muscle, heart, and brown adipose tissue.

SLU-PP-332 enhances ERRα transcriptional activity by stabilizing its active conformation and promoting coactivator recruitment (particularly PGC-1α, which is both an ERRα target gene and an ERRα coactivator, creating a positive feed-forward loop). Activated ERRα binds to ERR response elements (ERREs) in the promoter regions of hundreds of metabolic genes, upregulating the entire oxidative metabolism gene program: mitochondrial electron transport chain subunits, fatty acid oxidation enzymes, TCA cycle enzymes, and mitochondrial transcription and replication factors.

The most striking effect in preclinical studies is the transformation of skeletal muscle fiber type composition. SLU-PP-332 treatment increases the proportion of slow-twitch (type I) and oxidative fast-twitch (type IIA) fibers while decreasing glycolytic fast-twitch (type IIB/IIX) fibers. Type I fibers are rich in mitochondria, capillaries, and myoglobin — they are the fibers that endurance athletes develop through years of training. By pharmacologically shifting this fiber type ratio, SLU-PP-332 produces endurance capacity gains similar to what would require months of aerobic training. In mouse studies published in 2023, treated animals ran significantly longer and farther on treadmill tests. This ERRα-mediated mechanism is distinct from and potentially complementary to AMPK-based exercise mimetics like AICAR, as it targets a different node in the mitochondrial biogenesis regulatory network.